Literature DB >> 23170763

Alfentanil: correlations between absence of effect upon subcutaneous mast cells and absence of granuloma formation after intrathecal infusion in the dog.

Tony L Yaksh1, Joanne J Steinauer, Samantha L Veesart, Shelle A Malkmus.   

Abstract

BACKGROUND: We hypothesize that intrathecal (IT) granulomas arising from the IT infusion of several opiates may result from the degranulation of meningeal mast cells (MC). Given functional covariance between cutaneous and meningeal MC, we propose that opioids that do not degranulate cutaneous MC will not produce a granuloma. An opioid meeting this criteria is the phenylpiperadine alfentanil HCl.
METHODS: Three experiments were accomplished in dogs. 1) Cutaneous MC degranulation. Flare areas on the dog abdomen were measured after intradermal alfentanil, morphine, or compound 48-80. 2) Dose ranging of analgesic effects of IT alfentanil infusion. Dogs with lumbar IT catheters received continuous infusion for 24 hours of different concentrations (1-20 mg/mL/d) of alfentanil and analgesic effects were assessed. 3) Granuloma inducing effects. Dogs received IT alfentanil (20 mg/mL/d; N = 5; 22-28 days) or morphine (12 mg/mL/d; N = 3; 22-30 days) and spinal cord harvested for histopathology after 22-30 days of infusion.
RESULTS: 1) Intradermal morphine (10 mg/mL) and compound 48-80 (1 mg/mL) but not alfentanil at concentrations up to 20 mg/mL produced a cutaneous flare. IT alfentanil infusion produced increases in thermal escape latency at concentrations as low as 2 mg/mL/day. A significant depression of arousal was noted in the dogs receiving 20 mg/mL. Over the 22- to 30-day infusion period, morphine (12 mg/mL/day) resulted in granulomas in all three animals examined whereas IT alfentanil at 20 mg/mL/day failed to initiate a granuloma in any animal.
CONCLUSIONS: These results support the hypothesis linking MC degranulation and IT granulomas.
© 2012 International Neuromodulation Society.

Entities:  

Keywords:  Intraspinal drug delivery; intrathecal admixtures; intrathecal drug delivery; intrathecal granuloma; intrathecal pump; morphine; opioid

Mesh:

Substances:

Year:  2012        PMID: 23170763      PMCID: PMC3582801          DOI: 10.1111/j.1525-1403.2012.00534.x

Source DB:  PubMed          Journal:  Neuromodulation        ISSN: 1094-7159


  59 in total

1.  Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin.

Authors:  James A Blunk; Martin Schmelz; Susanne Zeck; Per Skov; Rudolf Likar; Wolfgang Koppert
Journal:  Anesth Analg       Date:  2004-02       Impact factor: 5.108

2.  Chronically infused intrathecal morphine in dogs.

Authors:  Tony L Yaksh; Kjersti A Horais; Nicolle A Tozier; Jeffrey W Allen; Michael Rathbun; Steven S Rossi; Claudia Sommer; Carol Meschter; Philip J Richter; Keith R Hildebrand
Journal:  Anesthesiology       Date:  2003-07       Impact factor: 7.892

3.  Morphologic changes associated with intrathecal catheters for direct delivery to the central nervous system in preclinical studies.

Authors:  Mark T Butt
Journal:  Toxicol Pathol       Date:  2010-12-08       Impact factor: 1.902

4.  Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients.

Authors:  Robert J Coffey; Kim Burchiel
Journal:  Neurosurgery       Date:  2002-01       Impact factor: 4.654

5.  Opiate pharmacology of intrathecal granulomas.

Authors:  Jeffrey W Allen; Kjersti A Horais; Nicolle A Tozier; Tony L Yaksh
Journal:  Anesthesiology       Date:  2006-09       Impact factor: 7.892

Review 6.  Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut.

Authors:  Hugh R P Miller; Alan D Pemberton
Journal:  Immunology       Date:  2002-04       Impact factor: 7.397

7.  Continuous intrathecal administration of shortlasting mu opioids remifentanil and alfentanil in the rat.

Authors:  H Buerkle; T L Yaksh
Journal:  Anesthesiology       Date:  1996-04       Impact factor: 7.892

Review 8.  Embryonic and fetal development of structures associated with the cerebro-spinal fluid in man and other species. Part I: The ventricular system, meninges and choroid plexuses.

Authors:  M Catala
Journal:  Arch Anat Cytol Pathol       Date:  1998

Review 9.  Neuraxial analgesia in neonates and infants: a review of clinical and preclinical strategies for the development of safety and efficacy data.

Authors:  Suellen M Walker; Tony L Yaksh
Journal:  Anesth Analg       Date:  2012-07-13       Impact factor: 5.108

10.  Mast cell chymase potentiates histamine-induced wheal formation in the skin of ragweed-allergic dogs.

Authors:  I Rubinstein; J A Nadel; P D Graf; G H Caughey
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 19.456

View more
  6 in total

1.  Mast Cell Degranulation and Fibroblast Activation in the Morphine-induced Spinal Mass: Role of Mas-related G Protein-coupled Receptor Signaling.

Authors:  Tony L Yaksh; Kelly A Eddinger; Shinichi Kokubu; Zhenping Wang; Anna DiNardo; Roshni Ramachandran; Yuelian Zhu; Yajun He; Fieke Weren; Daphne Quang; Shelle A Malkmus; Katherine Lansu; Wesley K Kroeze; Brian Eliceiri; Joanne J Steinauer; Peter W Schiller; Peter Gmeiner; Linda M Page; Keith R Hildebrand
Journal:  Anesthesiology       Date:  2019-07       Impact factor: 7.892

Review 2.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

3.  Role of meningeal mast cells in intrathecal morphine-evoked granuloma formation.

Authors:  Tony L Yaksh; Jeffery W Allen; Samantha L Veesart; Kjersti A Horais; Shelle A Malkmus; Miriam Scadeng; Joanne J Steinauer; Steve S Rossi
Journal:  Anesthesiology       Date:  2013-03       Impact factor: 7.892

4.  Characterization of Effect of Repeated Bolus or Continuous Intrathecal Infusion of Morphine on Spinal Mass Formation in the Dog.

Authors:  Keith R Hildebrand; Linda M Page; Tina M Billstrom; Joanne J Steinauer; Kelly A Eddinger; Shervin Arjomand; Tony L Yaksh
Journal:  Neuromodulation       Date:  2019-05-23

Review 5.  The Pharmacology of Spinal Opioids and Ziconotide for the Treatment of Non-Cancer Pain.

Authors:  J E Pope; T R Deer; K Amirdelfan; W P McRoberts; N Azeem
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

6.  Characterization of Analgesic Actions of the Chronic Intrathecal Infusion of H-Dmt-D-Arg-Phe-Lys-NH2 in Rat.

Authors:  Shinichi Kokubu; Kelly A Eddinger; Shigeki Yamaguchi; Lena Libertad Huerta-Esquivel; Peter W Schiller; Tony L Yaksh
Journal:  Neuromodulation       Date:  2019-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.